On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of booster vaccination against meningococci of serogroup C, reduction of antibiotic resistance, and dual pilot structure for diagnosis clarification in centers for rare diseases.